Get started
Work

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma

Year: 2013
Type: article
Abstract: Meeting abstracts T-VEC is a herpes simplex virus type-1-derived oncolytic immunotherapy designed to produce GM-CSF and to selectively replicate in and lyse tumors to induce a systemic anti-tumor immune response. A phase 3 study of T-VEC in Stage IIIB-IV melanoma demonstrated a significant
DOI: 10.1186/2051-1426-1-s1-p84
Authors: Igor Puzanov, Mohammed Milhem, Robert Andtbacka, David Minor, Omid Hamid, Ai Li, Ari VanderWalde, Howard Kaufman
Institutions: Vanderbilt University, University of Iowa, Huntsman Cancer Institute, Angeles Clinic and Research Institute, Amgen (United States), Rush University
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2053540544
FWCI: 0.178
Cites:
Cited by: 6
Related to: 10